<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486742</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 2019-2560</org_study_id>
    <nct_id>NCT04486742</nct_id>
  </id_info>
  <brief_title>Brief Cognitive Behavioral Therapy to Treat Itch Rumination &quot;Itch CBT&quot; in Eczema</brief_title>
  <official_title>Brief Cognitive Behavioral Therapy to Treat Itch Rumination &quot;Itch CBT&quot; in Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to adapt cognitive behavior therapy (CBT) to improve itch
      in children with eczema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eczema is characterized by chronic itch. Many children develop a chronic focus (rumination)
      on their itch. Rumination is a maladaptive method of responding to distress, in which the
      individual thinks obsessively about the source of distress. The rumination on chronic itch in
      eczema can have detrimental effects on one's quality of life, as well as induce significant
      anxiety about when itch will return, how long it will last, and how it will affect physical
      and social functioning.

      Cognitive behavior therapy (CBT) is a frontline treatment for rumination, as it focuses on
      teaching strategies so that the individual can examine distressing thoughts objectively and
      determine their validity, replace negative thinking patterns with more adaptive thought
      patterns, and increase the individual's awareness to their problematic thought patterns.
      Additionally, CBT helps the individual to implement behavioral strategies to cope with
      possibly anxiety-inducing situations, such as scratching while trying to go to sleep.

      The investigators hypothesize that an Itch CBT intervention is an effective,
      non-medication-based, easy to implement strategy to improve itch in children with eczema.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Itch Severity Numerical Rating Scale</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Numerical rating scale to assess itch severity, scale of 0-10, higher score means higher itch severity and worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Children's Dermatology Life Quality Index</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Questionnaire to assess impact of eczema on quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Itch Rumination Questionnaire</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Questionnaire to assess common fear and anxiety around itch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Anxiety and Depression</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Questionnaire to assess anxiety and depression symptoms in pediatric populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Pediatric Itch - Short Form 1 (2+6)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Questionnaire to assess level and severity of itch and common disturbances due to itch (social, emotional, physical)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Itch CBT Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the Itch CBT Arm will participate in 4 weekly telehealth sessions with a therapist to address common areas of anxiety related to atopic dermatitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized to the Usual Care Arm of the study will receive standard of care eczema educational materials that are typically provided by their health care provider after a clinic (or telehealth) visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Itch CBT</intervention_name>
    <description>Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.</description>
    <arm_group_label>Itch CBT Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe atopic dermatitis [assessed by Patient Oriented Eczema Measure
             (POEM)score of &gt;-8 OR NRS itch score of &gt;= 4].

          -  English speaking.

          -  Currently receiving treatment at Lurie Children's Hospital for atopic dermatitis.

          -  Parent or guardian available to participate in protocol.

          -  Have sufficient technology (e.g., cell phone, computer, tablet, etc.) that can be used
             to access Zoom conference technology for telemedicine visits.

        Exclusion Criteria:

          -  Inability to comprehend and complete questionnaires.

          -  History of intellectual disability or psychosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Paller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Taddeo, MPH</last_name>
    <phone>3125031469</phone>
    <email>michelle.taddeo@northwestern.edu</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Amy Paller</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04486742/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04486742/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

